David M. Jackman

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Scott Gettinger, Leora Horn, Leena Gandhi et al. · Journal of Clinical Oncology · 2015 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

David M. Jackman, William Pao, Gregory J. Riely et al. · Journal of Clinical Oncology · 2009 · 786 citations

Medicine, Oncology, Pharmacology +15

Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

Geoffrey R. Oxnard, Cloud P. Paweletz, Yanan Kuang et al. · Clinical Cancer Research · 2014 · 782 citations

Medicine, Genetics, Oncology +17

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

Scott Gettinger, Leora Horn, David M. Jackman et al. · Journal of Clinical Oncology · 2018 · 749 citations

Medicine, Oncology, Pharmacology +16

<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression

Mark M. Awad, Geoffrey R. Oxnard, David M. Jackman et al. · Journal of Clinical Oncology · 2016 · 688 citations · Full text

Medicine, Genetics, Oncology +17